Search Results

woman presented with several weeks of progressive fatigue, bruising, and eventually the development of fevers. She had no prior medical problems and took no medications. Physical examination revealed only moderate splenomegaly, measuring 14 cm. On

for <5% of all cases. 2 IMTs most often present with signs and symptoms restricted to the areas affected; however, 15% to 30% of people present with fever, weight loss, malaise, microcytic anemia, elevated erythrocyte sedimentation rate

, dysphagia, or dyspnea. He reported no significant weight loss, fevers, or chills, and had not noticed any other masses or unusual skin lesions. He did report mild fatigue. A brief trial of antibiotics was prescribed by a primary care physician but did not

first-line treatment in advanced colorectal cancer . J Clin Oncol 2000 ; 18 : 2938 – 2947 . 67. Crawford J Ozer H Stoller R . Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients

transplantation: analysis of factors associated with infection . Oral Surg Oral Med Oral Pathol 1990 ; 70 : 286 – 293 . 60. Bergmann OJ Mogensen SC Ellermann-Eriksen S Ellegaard J . Acyclovir prophylaxis and fever during remission-induction therapy

reduction. The treatment course with trametinib and dabrafenib continued for a total of 9 months. The patient experienced mild pyrexia (grade I fever according to CTCAE version 5.0.), which required treatment interruption for 4 days before later resuming the

onset abdominal pain and fevers, and imaging results were concerning for abscess formation at the anastomotic site. He underwent exploratory laparotomy, ileocolostomy resection, and abdominal washout with wide drainage for ileocolostomy perforation

to a nadir of 385 ng/mL at the time of disease progression. The patient’s treatment course was complicated by rash and fevers, which required low doses of prednisone and reduced doses of dabrafenib (100 mg orally twice daily) and trametinib (1.5 mg

delay in obtaining remaining tissue from the patient's FNA, the specimen tested positive for NMC with strong, diffuse NUT staining ( Figure 2 ). In the interim, the patient experienced worsening bone pain, dyspnea, and fever, and was hospitalized

who’ve been through the process already. The patient and family experience has been improved due to Moffitt’s nursing team’s efforts to provide dedicated education on the common side effects for CAR T-cell therapy, such as high fevers, neurotoxicity